We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation ("I&I") space. Helping patients and their families is the guiding principle at the heart of Barinthus Bio.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -31.42% to -49.00%, capital efficiency is deteriorating. Negative free cash flow of -$48M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$52M
▼ -8.8% YoY
Op. Margin
—
ROIC
-47.43%
▼ -17.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$36M
▼ -61.0% YoY
Op. Cash Flow (TTM)
-$36M
▼ -65.8% YoY
Net Debt
-$55M
Net Cash Position
Cash & Equiv.
$66M
Continue Research